Quick Answer
GALECTIN THERAPEUTICS INC reported Net Income of -$30.84 million for fiscal year 2025.
GALECTIN THERAPEUTICS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$30.84M +34.5% |
-$47.05M -14.6% |
-$41.07M -5.9% |
-$38.78M -27.0% |
-$30.53M -30.1% |
-$23.46M -76.5% |
| Diluted EPS | -$0.48 +36.8% |
-$0.76 -2.7% |
-$0.74 -13.8% |
-$0.65 -25.0% |
-$0.52 -26.8% |
-$0.41 |
| Total Assets | $19.53M +11.6% |
$17.50M -38.0% |
$28.20M +32.5% |
$21.29M -49.1% |
$41.83M +41.3% |
$29.60M -38.9% |
| Cash and Equivalents | $17.72M +17.2% |
$15.12M -41.1% |
$25.66M +38.0% |
$18.59M -53.1% |
$39.65M +46.1% |
$27.14M -42.8% |
| Stockholders Equity | -$127.92M -22.1% |
-$104.79M -69.1% |
-$61.96M -82.7% |
-$33.92M -3898.1% |
$893.0K -96.0% |
$22.47M -48.8% |
| R&D Expense | $14.29M -60.9% |
$36.57M +13.8% |
$32.13M +1.2% |
$31.74M +33.2% |
$23.82M +32.5% |
$17.98M +140.7% |
| Operating Income | -$20.09M +52.7% |
-$42.43M -11.5% |
-$38.07M +0.7% |
-$38.35M -27.1% |
-$30.18M -28.7% |
-$23.44M -74.5% |
| Shares Outstanding | 65.20M +3.2% |
63.16M +2.1% |
61.85M +4.1% |
59.43M +0.1% |
59.34M +4.0% |
57.08M +0.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$8.18M | +27.1% | -8.8% |
| Diluted EPS | September 30, 2025 | -$0.13 | +27.8% | -8.3% |
| Total Assets | September 30, 2025 | $12.87M | -55.6% | -17.5% |
| Cash and Equivalents | September 30, 2025 | $11.53M | -57.4% | -16.3% |
| Stockholders Equity | September 30, 2025 | -$125.30M | -33.0% | -5.4% |
| R&D Expense | September 30, 2025 | $2.61M | -65.6% | -19.9% |
| Operating Income | September 30, 2025 | -$4.20M | +53.7% | +9.2% |
| Shares Outstanding | September 30, 2025 | 64.47M | +3.5% | +0.6% |
- GALECTIN THERAPEUTICS INC reported Net Income of -$30.84 million for fiscal year 2025.
- GALECTIN THERAPEUTICS INC showed an increase of +34.5% in Net Income compared to the prior fiscal year.
- GALECTIN THERAPEUTICS INC reported Diluted EPS of $0.48 per share (loss) for fiscal year 2025.
- GALECTIN THERAPEUTICS INC showed an increase of +36.8% in Diluted EPS compared to the prior fiscal year.
- GALECTIN THERAPEUTICS INC reported Total Assets of $19.53 million for fiscal year 2025.
- GALECTIN THERAPEUTICS INC showed an increase of +11.6% in Total Assets compared to the prior fiscal year.
- GALECTIN THERAPEUTICS INC reported Cash and Equivalents of $17.72 million for fiscal year 2025.
- GALECTIN THERAPEUTICS INC showed an increase of +17.2% in Cash and Equivalents compared to the prior fiscal year.
- GALECTIN THERAPEUTICS INC reported Stockholders Equity of -$127.92 million for fiscal year 2025.
- GALECTIN THERAPEUTICS INC showed a decrease of -22.1% in Stockholders Equity compared to the prior fiscal year.
- GALECTIN THERAPEUTICS INC reported R&D Expense of $14.29 million for fiscal year 2025.
- GALECTIN THERAPEUTICS INC showed a decrease of -60.9% in R&D Expense compared to the prior fiscal year.
- GALECTIN THERAPEUTICS INC reported Operating Income of -$20.09 million for fiscal year 2025.
- GALECTIN THERAPEUTICS INC showed an increase of +52.7% in Operating Income compared to the prior fiscal year.
- GALECTIN THERAPEUTICS INC reported Shares Outstanding of 65.20 million shares for fiscal year 2025.
- GALECTIN THERAPEUTICS INC showed an increase of +3.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: